StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3062% below fair value
$0.20+0.00 (+0.25%)

Close on Nov 13, 2026Market cap $2.61MP/E –Yield –

Earnings

20/20 Biolabs's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$700.00K
EPS, Q2 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of 20/20 Biolabs's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 17, 2026after the close$700.00K––Release
Q1 FY2026ended Mar 31, 2026May 20, 2026after the close$400.00K–-$0.28Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

20/20 Biolabs has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When 20/20 Biolabs puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases 20/20 Biolabs filed with the SEC as exhibits to Form 8-K or 6-K

  1. Investor Webinar NASDAQ: AIDX September 2, 2026
    Update
  2. PRESS RELEASE ISSUED ON AUGUST 17, 2026
    Results
  3. 8-K exhibit EX-99.1
    Update
  4. 8-K exhibit EX-99.1
    Update
  5. PRESS RELEASE ISSUED ON MAY 20, 2026
    Results
  6. PRESS RELEASE ISSUED ON MARCH 31, 2026
    Results

See a number that looks wrong?